Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib

Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib

Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of adverse events. Here we report a male patient with metastatic melanoma who experienced life-threatening colitis and duodenitis following treatment with ipilimumab and nivolumab. The patient did not respond to the...

Full description

Bibliographic Details
Main Authors: Mark W. D. Sweep, Martijn J. H. Tjan, Mark A. J. Gorris, Kalijn F. Bol, Harm Westdorp
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
colitis
immune checkpoint inhibitor
tofacitinib
adverse event
cancer
autoimmunity
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212432/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212432/full

Similar Items